Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 5
1995 2
1996 1
1997 3
1998 5
1999 11
2000 5
2001 3
2002 5
2003 6
2004 3
2005 8
2006 6
2007 6
2008 6
2009 10
2010 10
2011 9
2012 4
2013 19
2014 11
2015 10
2016 20
2017 11
2018 11
2019 14
2020 20
2021 15
2022 21
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Results by year

Filters applied: . Clear all
Page 1
EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z, Chen J, Ren D, Zhang J, Yang Y, Zhang H, Mao B, Ma H. Chen Z, et al. Aging (Albany NY). 2020 Dec 3;13(1):598-618. doi: 10.18632/aging.202169. Epub 2020 Dec 3. Aging (Albany NY). 2020. PMID: 33288738 Free PMC article.
Additionally, EPHA5 mutation cooccurred with homologous recombination (HR) or mismatch repair (MMR) gene mutations. ...Our results revealed the correlation of EPHA5 mutations with tumor immune microenvironment and predictive factors for immunotherapy, implying the p …
Additionally, EPHA5 mutation cooccurred with homologous recombination (HR) or mismatch repair (MMR) gene mutations. ...Our results re …
EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway.
Zhang R, Han D, Li L, Luo W, Liu J, Qian L. Zhang R, et al. Cancer Manag Res. 2020 Oct 2;12:9539-9549. doi: 10.2147/CMAR.S261182. eCollection 2020. Cancer Manag Res. 2020. PMID: 33061640 Free PMC article.
However, the role of EphA5 in radiotherapy for ESCC remains unclear. METHODS: The siRNA sequences against human EPHA5 were transfected to the ESCC cells (KYSE150 and KYSE450). ...RESULTS: CCK8 assay and clonogenic assay showed that the proliferation of EphA5- …
However, the role of EphA5 in radiotherapy for ESCC remains unclear. METHODS: The siRNA sequences against human EPHA5 were tra …
Expression of EPHA5 in lung adenocarcinoma is associated with lymph node metastasis and EGFR mutation.
Liu C, He Y, Feng X, Li J, Wang J. Liu C, et al. APMIS. 2022 Jun;130(6):338-345. doi: 10.1111/apm.13222. Epub 2022 Apr 4. APMIS. 2022. PMID: 35332588
EPHA5 is a member of the Eph family of tyrosine kinase receptors, which affect carcinogenesis. ...EPHA5 was knocked down in NCI-H460 and H1299 lung cancer cell lines using siRNAs. ...
EPHA5 is a member of the Eph family of tyrosine kinase receptors, which affect carcinogenesis. ...EPHA5 was knocked down in NC …
EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.
Huang W, Lin A, Luo P, Liu Y, Xu W, Zhu W, Wei T, Lyu Q, Guo L, Zhang J. Huang W, et al. Cancer Gene Ther. 2021 Aug;28(7-8):864-874. doi: 10.1038/s41417-020-0207-6. Epub 2020 Aug 6. Cancer Gene Ther. 2021. PMID: 32759987
LUAD patients with EPHA5 mutations in the immunotherapy cohort achieved a longer progression-free survival (PFS) time than patients with wild-type EPHA5. Immune response pathways were among the top enriched pathways in samples with EPHA5 mutations. In additio …
LUAD patients with EPHA5 mutations in the immunotherapy cohort achieved a longer progression-free survival (PFS) time than patients w …
EphA5 knockdown enhances the invasion and migration ability of esophageal squamous cell carcinoma via epithelial-mesenchymal transition through activating Wnt/beta-catenin pathway.
Zhang R, Liu J, Zhang W, Hua L, Qian LT, Zhou SB. Zhang R, et al. Cancer Cell Int. 2020 Jan 13;20:20. doi: 10.1186/s12935-020-1101-x. eCollection 2020. Cancer Cell Int. 2020. PMID: 31956298 Free PMC article.
However, the role of EphA5 in esophageal squamous cell carcinoma (ESCC) is not clear. ...The invasion and migration of ESCC cells were accelerated after EphA5 knockdown. The expression of EMT biomarkers was altered in ESCC cells transfected with siRNA targeting E …
However, the role of EphA5 in esophageal squamous cell carcinoma (ESCC) is not clear. ...The invasion and migration of ESCC cells wer …
EPHA5 Enhances the Stemness of Non-small cell lung cancer Cells Through Activating the Wnt Signaling Pathway.
Li J, Zhu Y. Li J, et al. J BUON. 2021 Sep-Oct;26(5):1871-1878. J BUON. 2021. PMID: 34761594 Free article.
RESULTS: The expression level of EPHA5 in non-small cell lung cancer H460 and H1229 cells was higher than that in A549 and SPC-A1 cells. After EPHA5 silencing, the levels of CD133 and stemness markers Sox2, Nanog, KLF4 and Oct4 in H460 and H1229 cells all declined. …
RESULTS: The expression level of EPHA5 in non-small cell lung cancer H460 and H1229 cells was higher than that in A549 and SPC-A1 cel …
EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion.
Zhang J, Zhang Z, Song W, Liu J. Zhang J, et al. Mol Cell Probes. 2020 Aug;52:101566. doi: 10.1016/j.mcp.2020.101566. Epub 2020 Mar 28. Mol Cell Probes. 2020. PMID: 32234341
METHODS: EPHA5-wt (wild type) and EPHA5-mut (mutation) plasmids were constructed. ...In contrast, EPHA5-wt overexpression and EPHA5 silencing exerted the opposite effect. ...
METHODS: EPHA5-wt (wild type) and EPHA5-mut (mutation) plasmids were constructed. ...In contrast, EPHA5-wt overexpressi …
EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li Y, Chu J, Feng W, Yang M, Zhang Y, Zhang Y, Qin Y, Xu J, Li J, Vasilatos SN, Fu Z, Huang Y, Yin Y. Li Y, et al. FASEB J. 2019 Apr;33(4):4851-4865. doi: 10.1096/fj.201701561RRRR. Epub 2019 Jan 8. FASEB J. 2019. PMID: 30620624
In this study, deletion of EPHA5 can significantly increase the resistance of HER2-positive breast cancer patients to trastuzumab. To investigate how EPHA5 deficiency induces trastuzumab resistance, clustered regularly interspaced short palindromic repeat technology …
In this study, deletion of EPHA5 can significantly increase the resistance of HER2-positive breast cancer patients to trastuzumab. To …
Association between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer.
Han X, Liu T, Zhai J, Liu C, Wang W, Nie C, Wang Q, Zhu X, Zhou H, Tian W. Han X, et al. PeerJ. 2022 Sep 21;10:e13774. doi: 10.7717/peerj.13774. eCollection 2022. PeerJ. 2022. PMID: 36164608 Free PMC article.
RESULTS: After PS adjustment, EPHA5 Pm (positive methylation) was more likely to increase the GC risk than EPHA5 Nm (negative methylation) (OR(b) = 1.827, 95% CI [1.202-2.777], P = 0.005). ...In addition, no convincing association was found between EPHA5 Pm a …
RESULTS: After PS adjustment, EPHA5 Pm (positive methylation) was more likely to increase the GC risk than EPHA5 Nm (negative …
Downregulation of EphA5 by promoter methylation in human prostate cancer.
Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, Wu Z, Wang H, Xu X, Zhang H, Ren G, Tang J, Li X, Guan M. Li S, et al. BMC Cancer. 2015 Jan 22;15:18. doi: 10.1186/s12885-015-1025-3. BMC Cancer. 2015. PMID: 25609195 Free PMC article.
BACKGROUND: EphA5 is a member of the Eph/ephrin family and plays a critical role in the regulation of carcinogenesis. ...As less is known about the mechanism of EphA5 downregulation and the function of EphA5, here we investigated the expression and an epigene …
BACKGROUND: EphA5 is a member of the Eph/ephrin family and plays a critical role in the regulation of carcinogenesis. ...As less is k …
246 results